Mechanistic description
The TREM2/DAP12 signaling pathway normally functions as a critical gatekeeper preventing trans-synaptic tau propagation through specialized microglial surveillance at synaptic clefts. TREM2 receptors on microglial processes positioned at tripartite synapses detect extracellular tau oligomers released from presynaptic terminals through direct binding to tau’s microtubule-binding domain. Upon tau detection, TREM2-DAP12 activation triggers rapid Syk-mediated phosphorylation cascades that mobilize microglial engulfment machinery specifically targeting tau-containing synaptic vesicles and dendritic spines. This process involves CX3CR1-mediated microglial positioning and complement receptor CR3 activation for synaptic material phagocytosis. When TREM2 function is compromised by pathogenic variants (R47H, R62H), the surveillance system fails, allowing tau oligomers to accumulate in synaptic clefts where they bind to postsynaptic NMDA and AMPA receptors. This tau-receptor interaction facilitates tau internalization through clathrin-mediated endocytosis and subsequent retrograde transport via dynein motors along microtubules to the soma. Once internalized, exogenous tau seeds recruit endogenous tau through templated misfolding, initiating intracellular neurofibrillary tangle formation. The mechanism is amplified by defective microglial IL-10 and TGF-β production downstream of impaired TREM2 signaling, which normally suppresses neuronal tau hyperphosphorylation via GSK-3β inhibition. Additionally, reduced microglial-derived BDNF and insulin-like growth factor-1 compromises neuronal proteostasis machinery, further accelerating tau aggregation. This synaptic-focused dysfunction explains the stereotypical anatomical progression of tau pathology along known connectivity patterns in Alzheimer’s disease, as TREM2-deficient microglia fail to interrupt tau’s trans-neuronal spread through vulnerable circuit networks including the default mode network and limbic connections.
Mechanism / pathway
- TREM2
- TREM2/DAP12 signaling with secondary synaptic surveillance disruption
- neuroscience
Evidence for (14)
Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance
Hippocampal interneurons shape spatial coding alterations in neurological disorders
TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration.
Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.
Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus.
Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17.
Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.
Progressive Supranuclear Palsy-A Global Review.
Alzheimer's disease basics: we all should know.
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.
NAD(+) restores proteostasis through splicing-dependent autophagy.
A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.
Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy.
TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, leading to anxiety-like behaviors.
Evidence against (4)
CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.
Viral and non-viral cellular therapies for neurodegeneration.
Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights.
Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders.
Evidence matrix
Supporting
- Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance PMID:31285742
- Hippocampal interneurons shape spatial coding alterations in neurological disorders PMID:40392508
- TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration. PMID:41642658 · 2026 · J Clin Invest
- Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies. PMID:41804841 · 2026 · Alzheimers Dement
- Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus. PMID:41767305 · 2026 · Front Genet
- Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17. PMID:41822813 · 2026 · Sleep Adv
- Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque. PMID:41695270 · 2026 · Front Aging Neurosci
- Progressive Supranuclear Palsy-A Global Review. PMID:40898879 · 2026 · Mov Disord Clin Pract
- Alzheimer's disease basics: we all should know. PMID:40639927 · 2026 · Neurol Res
- Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks. PMID:41714746 · 2026 · Nat Med
- NAD(+) restores proteostasis through splicing-dependent autophagy. PMID:41313318 · 2026 · Autophagy
- A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology. PMID:41491101 · 2026 · Nat Med
- Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy. PMID:20301376 · 1993
- TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, leading to anxiety-like behaviors. PMID:41930604 · 2026 · J Alzheimers Dis
Contradicting
- CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. PMID:41931258 · 2026 · Acta Neurol Belg
- Viral and non-viral cellular therapies for neurodegeneration. PMID:41585268 · 2025 · Front Med (Lausanne)
- Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights. PMID:41619411 · 2026 · J Prev Alzheimers Dis
- Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders. PMID:41828591 · 2026 · Int J Mol Sci
Top-ranked evidence
trust_score × relevance_score × exp(-recency_weight × recency_days / 365)
Supports · top 3
- #1 paper-pmid-37371067 0.236
- #2 paper-44b62dd57aef 0.236
- #3 paper-136b59410d9c 0.236
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). TREM2-Mediated Microglial Dysfunction Impairs Synaptic Tau Propagation Blockade. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-var-fcc307041a
@misc{scidex_hypothesis_hvarfcc3,
title = {TREM2-Mediated Microglial Dysfunction Impairs Synaptic Tau Propagation Blockade},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-var-fcc307041a},
note = {SciDEX artifact hypothesis:h-var-fcc307041a}
}